<DOC>
	<DOC>NCT02954016</DOC>
	<brief_summary>To evaluate the safety and efficacy of the endoscopically implanted ValenTx EndoPass™ System for treatment of adults with severe obesity. The EndoPass System is indicated for weight loss in adults with a body mass index (BMI) ≥35 and ≤ 50 kg/m2 who have failed more conservative weight loss methods.</brief_summary>
	<brief_title>The ePass Clinical Trial for the Treatment of Obese Subjects</brief_title>
	<detailed_description>- Single-arm, multi-center study conducted in up to 50 subjects at up to 5 sites. - Subjects will be implanted with the EndoPass device for up to 36 months. - Body weight, adverse events and device function will be monitored at monthly visits for the first year after implant and quarterly visits thereafter. - Additional follow-up data will include vital signs, hip and waist circumference, blood lab tests, endoscopic and esophagram assessments of the condition of the implanted device, quality of life and eating behavior questionnaires. - All subjects will be followed for 12 months after device removal. - A single device renewal may take place as needed after the initial implant. - Subject study participation may last up to four years, but is expected to vary with implant duration, which will be determined on a case-by-case basis.</detailed_description>
	<criteria>Key 1860 years of age. BMI ≥ 35 and ≤ 50 kg/m2 Documented failure with nonsurgical weight loss methods Selfreported maximum and minimum body weights during the past 12 months within 10% of current body weight Key Pregnancy or intention of becoming pregnant. Past history of esophageal, gastric or bariatric surgery. Medical conditions contraindicating elective endoscopic or bariatric procedures. Insulindependent diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Weight Loss</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Hyperlipidemia</keyword>
</DOC>